BCHE and Alzheimer disease: Inhibitors of cholinesterases, the enzymes that catalyze the breakdown of acetylcholine, increase the endogenous level of acetylcholine by reducing the catalysis and enhance the cholinergic transmission in the brain, leading to improvement of memory and cognition in AD patients [3, 4].